KR20070087606A - 인자 ｘａ 억제제의 결정질 형태 - Google Patents

인자 ｘａ 억제제의 결정질 형태 Download PDF

Info

Publication number
KR20070087606A
KR20070087606A KR1020077013364A KR20077013364A KR20070087606A KR 20070087606 A KR20070087606 A KR 20070087606A KR 1020077013364 A KR1020077013364 A KR 1020077013364A KR 20077013364 A KR20077013364 A KR 20077013364A KR 20070087606 A KR20070087606 A KR 20070087606A
Authority
KR
South Korea
Prior art keywords
crystalline
pyridin
phenyl
compound
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077013364A
Other languages
English (en)
Korean (ko)
Inventor
마이클 제이. 오르와트
마리 에프. 말레이
록사나 에프. 쉬람
스티븐 알. 파비안
빙-시오우 양
빅터 더블유 로소
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20070087606A publication Critical patent/KR20070087606A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020077013364A 2004-12-15 2005-12-14 인자 ｘａ 억제제의 결정질 형태 Withdrawn KR20070087606A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US60/636,387 2004-12-15
US73798505P 2005-11-18 2005-11-18
US60/737,985 2005-11-18

Publications (1)

Publication Number Publication Date
KR20070087606A true KR20070087606A (ko) 2007-08-28

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077013364A Withdrawn KR20070087606A (ko) 2004-12-15 2005-12-14 인자 ｘａ 억제제의 결정질 형태

Country Status (15)

Country Link
US (2) US7371864B2 (enExample)
EP (1) EP1828187A2 (enExample)
JP (1) JP2008524228A (enExample)
KR (1) KR20070087606A (enExample)
AR (1) AR053990A1 (enExample)
AU (1) AU2005317158A1 (enExample)
BR (1) BRPI0519331A2 (enExample)
CA (1) CA2589886A1 (enExample)
IL (1) IL183825A0 (enExample)
MX (1) MX2007006919A (enExample)
NO (1) NO20072666L (enExample)
PE (1) PE20060739A1 (enExample)
RU (1) RU2007126770A (enExample)
TW (1) TW200634011A (enExample)
WO (1) WO2006065853A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636757B1 (en) 2008-05-27 2016-11-23 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
GEP20074098B (en) * 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
BRPI0519331A2 (pt) 2009-01-20
US7371864B2 (en) 2008-05-13
JP2008524228A (ja) 2008-07-10
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
WO2006065853A3 (en) 2006-08-24
NO20072666L (no) 2007-09-07
AR053990A1 (es) 2007-05-30
MX2007006919A (es) 2007-06-26
WO2006065853A2 (en) 2006-06-22
CA2589886A1 (en) 2006-06-22
EP1828187A2 (en) 2007-09-05
PE20060739A1 (es) 2006-08-16
AU2005317158A1 (en) 2006-06-22
RU2007126770A (ru) 2009-01-27
US20080188517A1 (en) 2008-08-07
IL183825A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
JP6154473B2 (ja) 第ＸＩａ因子阻害剤の結晶形
KR20230121761A (ko) 인테그린 억제제 및 그의 용도
JP2023521411A (ja) （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体
US20080188517A1 (en) Crystalline forms of a factor xa inhibitor
US7829711B2 (en) Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
JP4177663B2 (ja) 新規な結晶形のＸａ因子阻害剤
JP5796872B2 (ja) 第Ｘａ因子阻害剤の結晶性塩
US7388096B2 (en) Crystalline forms of a factor Xa inhibitor
JP7473554B2 (ja) Ｐａｒ４阻害剤の結晶体
HK1212333B (en) Crystalline forms of a factor xia inhibitor
CN101065378A (zh) 作为因子Xa抑制剂的吡唑并[3,4－c]吡啶的晶型

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid